NuChem Sciences Overview
- Founded
- 2011

- Status
- Private
- Employees
- 83

- Latest Deal Type
- PE Growth
- Financing Rounds
- 3
- Investments
- 2
NuChem Sciences General Information
Description
Provider of medical contract research services intended to identify and optimize pre-clinical candidates in the area of small molecule drug discovery. The company's services specialize in the field of medicinal chemistry, drug discovery biology and can provide custom synthesis of compounds, structure-activity-relationship design, computational drug design, enabling international biotech and pharmaceuticals industries to move their project forward quickly and efficiently.
Contact Information
- 2350 rue Cohen
- Suite 201
- Saint-Laurent, Quebec H4R 2N6
- Canada
NuChem Sciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore NuChem Sciences‘s full profile, request access.
Request a free trialNuChem Sciences Comparisons
Industry
000 0000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialNuChem Sciences Competitors (3)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CTI Clinical Trial & Consulting Services | Private Debt Financed | Covington, KY | 0000 | 000000000 - | ||
0000000000 | Private Equity-Backed | Cuxhaven, Germany | 00 | 000000000000 | ||
000000 000000 | Corporation | Montreal, Canada |
NuChem Sciences Patents
NuChem Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-2984073-A1 | Inhibitors of polynucleotide repeat-associated rna foci and uses thereof | Abandoned | 27-Oct-2017 | 0000000000 | |
AU-2014231330-A1 | Small molecule modulators of pcsk9 and methods of use thereof | Abandoned | 15-Mar-2013 | 0000000000 | |
JP-2016511274-A | Pcsk9 small molecule modulator and method of use thereof | Pending | 15-Mar-2013 | 0000000000 | 0 |
EP-2961765-A1 | Small molecule modulators of pcsk9 and methods of use thereof | Withdrawn | 15-Mar-2013 | 0000000000 | |
CA-2905237-A1 | Small molecule modulators of pcsk9 and methods of use thereof | Abandoned | 15-Mar-2013 | C07K5/0827 |
NuChem Sciences Executive Team (7)
NuChem Sciences Board Members (3)
Name | Representing | Role | Since |
---|---|---|---|
0000 00000 | NuChem Sciences | Co-Owner, President & Chairman | 000 0000 |
NuChem Sciences Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialNuChem Sciences Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore NuChem Sciences‘s full profile, request access.
Request a free trialNuChem Sciences Investments (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000000 | 17-Aug-2021 | 0000000000 | 000.00 | Drug Discovery | 0000 0000 |
Amplia Pharmatek | 31-Oct-2019 | Buyout/LBO | Drug Discovery | 0000 0000 |
NuChem Sciences Subsidiaries (2)
Company Name | Industry | Location | Founded |
---|---|---|---|
Amplia Pharmatek | Drug Discovery | Montreal, Canada | 2009 |
000000000 | Drug Discovery | Levis, Canada | 0000 |